1 alpha-hydroxyvitamin D3 in intestinal calcium malabsorption. A pilot study.
The effect of oral 1 alpha-hydroxyvitamin D3 (1 alpha (OH)D3) was studied in six patients with calcium malabsorption and steatorrhoea due to small-intestinal resection or small-bowel disease. After 3 months of treatment with 1 alpha (OH)D3 a significant increase in calcium absorption, but not in bone mineral content (BMC), was observed. During treatment urinary calcium increased significantly. We conclude that comparative long-term studies should be carried out to determine the effect and side effects of 1 alpha (OH)D3 and conventional vitamin D in calcium malabsorption after small-intestinal resections.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D002446:Celiac Disease / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D007421:Intestine, Small / Q000601:surgery; D008286:Malabsorption Syndromes / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism; D010865:Pilot Projects
D006887:Hydroxycholecalciferols; D008903:Minerals; D002118:Calcium; C008088:alfacalcidol